glp-1 signaling Receptor Agonists as Treatments for Type 2 Diabetes Regulation of GLP-1 and Glucagon

Audit Alert Do NOT code E11.40 (diabetic neuropathy, unspecified) when a more specific diabetic neuropathy code is documented: E11.41 (mononeuropathy), E11.42 (polyneuropathy), E11.43 (autonomic neuropathy), E11.44 (amyotrophy), or E11.49 (other)

Why Consistency Matters for Long-Term Results GLP-1 medications influence appetite and metabolism gradually over time

Losing weight shouldnt feel like banging my head against a wall, but thats how its been

Patent Protection Creates Limited Market Competition Novo Nordisk holds the primary patents on semaglutide (Ozempic, Wegovy), while Eli Lilly controls tirzepatide (Zepbound, Mounjaro)